TY - JOUR
T1 - Risk factors for lipodystrophy in the CISAI cohort
AU - Bonfanti, Paolo
AU - Gulisano, Cecilia
AU - Ricci, Elena
AU - Timillero, Lia
AU - Valsecchi, Laura
AU - Carradori, Silvia
AU - Pusterla, Luigi
AU - Fortuna, Paolo
AU - Miccolis, Sebastiano
AU - Magnani, Carlo
AU - Gabbuti, Andrea
AU - Parazzini, Fabio
AU - Martinelli, Canio
AU - Faggion, Ivano
AU - Landonio, Simona
AU - Quirino, Tiziana
AU - Vigevani, GianMarco
PY - 2003/11
Y1 - 2003/11
N2 - Purpose. - This study set out to describe the frequency of lipodystrophy, and identify its risk factors, in HIV-positive patients treated with HAART containing at least one protease inhibitor (PI). We analyzed the data collected in the CISAI study. Method. - The CISAI is a multicenter cohort study that has enrolled 1480 patients. We assessed whether patients had lipodystrophy at a medical visit, with follow-up visits by the same physician at least every 2 months, and also on the basis of patients' own reports. Results. - The lipodystrophy syndrome was detected in about 25% of the patients. Multivariate analysis showed the risk of lipodystrophy was correlated with female sex (RR 1.5; 95% confidence interval, CI, 1.2-2.1), with older age, with homosexuality (RR 1.5; 95% CI 1.0-2.4), with overt disease (RR 1.4; 95% CI 1.1-1.8) and with the duration of treatment before entering this study. The RR for ritonavir was higher than for the other PI (RR 1.4; 95% CI 0.9-1.9). Among patients receiving concomitant antiretroviral therapy the risk of lipodystrophy was greater with stavudine (RR 1.7; 95% CI 1.3-2.3). Conclusions. - The study confirmed the high frequency of the lipodystrophy syndrome among patients treated with PI.
AB - Purpose. - This study set out to describe the frequency of lipodystrophy, and identify its risk factors, in HIV-positive patients treated with HAART containing at least one protease inhibitor (PI). We analyzed the data collected in the CISAI study. Method. - The CISAI is a multicenter cohort study that has enrolled 1480 patients. We assessed whether patients had lipodystrophy at a medical visit, with follow-up visits by the same physician at least every 2 months, and also on the basis of patients' own reports. Results. - The lipodystrophy syndrome was detected in about 25% of the patients. Multivariate analysis showed the risk of lipodystrophy was correlated with female sex (RR 1.5; 95% confidence interval, CI, 1.2-2.1), with older age, with homosexuality (RR 1.5; 95% CI 1.0-2.4), with overt disease (RR 1.4; 95% CI 1.1-1.8) and with the duration of treatment before entering this study. The RR for ritonavir was higher than for the other PI (RR 1.4; 95% CI 0.9-1.9). Among patients receiving concomitant antiretroviral therapy the risk of lipodystrophy was greater with stavudine (RR 1.7; 95% CI 1.3-2.3). Conclusions. - The study confirmed the high frequency of the lipodystrophy syndrome among patients treated with PI.
KW - Adverse reactions
KW - Antiretroviral therapy
KW - Lipodystrophy
KW - Protease inhibitors
UR - http://www.scopus.com/inward/record.url?scp=0344256537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0344256537&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2003.06.002
DO - 10.1016/j.biopha.2003.06.002
M3 - Article
C2 - 14652168
AN - SCOPUS:0344256537
VL - 57
SP - 422
EP - 427
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
SN - 0753-3322
IS - 9
ER -